Literature DB >> 4082102

Polymerization properties of two normally circulating fibrinogens, HMW and LMW. Evidence that the COOH-terminal end of the a-chain is of importance for fibrin polymerization.

B Holm, F Brosstad, P Kierulf, H C Godal.   

Abstract

The plasma fibrinogen fractions HMW (mw 340,000) and LMW (mw 305,000) were prepared from purified (beta-alanine precipitated) fibrinogen by step-wise precipitation with ammonium sulfate. The thrombin clotting times were 14" and 20" respectively. The enzymatic phase of coagulation, measured as release of fibrinopeptide-A during incubation with thrombin, was found to be identical for HMW and LMW. Polymerization was studied by light scattering (at 605 nm) using preformed monomers (des-AA and des-AABB) prepared from HMW and LMW in the presence of 3.3 M urea by incubation with thrombin (100 NIH U/ml final conc.) and reptilase (1 U/ml final conc.). The HMW-monomers polymerised at a substantially higher rate than the corresponding LMW-monomers. Thus, the prolonged clotting time of LMW was explained by retarded polymerization. It is suggested that the -COOH terminal end of the a-chain, containing the molecular difference between HMW and LMW, is of importance for polymerization. Furthermore, the release of fibrinopeptide B (des-AABB-monomers) improved polymerization properties in HMW as well as in LMW, and all types of monomers polymerised more rapidly in the presence of Ca++.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4082102     DOI: 10.1016/0049-3848(85)90239-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  3 in total

1.  Direct evidence for specific interactions of the fibrinogen alphaC-domains with the central E region and with each other.

Authors:  Rustem I Litvinov; Sergiy Yakovlev; Galina Tsurupa; Oleg V Gorkun; Leonid Medved; John W Weisel
Journal:  Biochemistry       Date:  2007-07-13       Impact factor: 3.162

2.  High-level expression and preparation of recombinant human fibrinogen as biopharmaceuticals.

Authors:  Masaki Hirashima; Takayuki Imamura; Kentaro Yano; Ryoichi Kawamura; Akihiro Meta; Yoshiyuki Tokieda; Toshihiro Nakashima
Journal:  J Biochem       Date:  2015-10-15       Impact factor: 3.387

3.  Fibrinogen Dusart: electron microscopy of molecules, fibers and clots, and viscoelastic properties of clots.

Authors:  J P Collet; J L Woodhead; J Soria; C Soria; M Mirshahi; J P Caen; J W Weisel
Journal:  Biophys J       Date:  1996-01       Impact factor: 4.033

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.